ストックスクリーナーアプリを入手
78.69
5.27%
-4.38
アフターアワーズ：
78.90
0.21
+0.27%
前日終値:
$83.07
開ける：
$79.94
24時間の取引高:
20.67M
Relative Volume:
3.01
時価総額：
$349.44B
収益：
$39.36B
当期純損益:
$13.79B
株価収益率:
25.50
EPS:
3.086
ネットキャッシュフロー:
$9.83B
1週間 パフォーマンス:
-8.78%
1か月 パフォーマンス:
-27.15%
6か月 パフォーマンス:
-41.89%
1年 パフォーマンス:
-26.24%
1日の値動き範囲:
$78.17
$80.88
1週間の範囲:
$78.17
$84.72
52週間の値動き範囲:
$78.17
$148.15
Novo Nordisk Adr Stock (NVO) Company Profile
NVO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
78.69 | 349.44B | 39.36B | 13.79B | 9.83B | 3.086 |
|
LLY
Lilly Eli Co
|
725.72 | 689.73B | 40.86B | 8.37B | -2.28B | 9.25 |
|
JNJ
Johnson Johnson
|
147.03 | 344.63B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
171.56 | 303.17B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
97.92 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-06 | アップグレード | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-04-12 | 開始されました | BMO Capital Markets | Outperform |
| 2024-01-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-16 | 再開されました | UBS | Neutral |
| 2023-12-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-02 | 開始されました | Argus | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2022-07-15 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | ダウングレード | UBS | Neutral → Sell |
| 2022-06-27 | アップグレード | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-05-31 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-04-25 | アップグレード | Cowen | Market Perform → Outperform |
| 2022-04-12 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-01-25 | ダウングレード | Liberum | Hold → Sell |
| 2021-12-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-12-17 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2021-01-20 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-07-06 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-05-11 | ダウングレード | UBS | Buy → Neutral |
| 2020-05-04 | 開始されました | Cowen | Market Perform |
| 2020-03-16 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-11-18 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-09-17 | アップグレード | Citigroup | Neutral → Buy |
| 2019-08-30 | ダウングレード | Jefferies | Hold → Underperform |
| 2019-06-20 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2019-06-11 | アップグレード | Barclays | Underweight → Equal Weight |
| 2019-04-29 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | 開始されました | Exane BNP Paribas | Outperform |
| 2018-12-11 | 再開されました | Jefferies | Hold |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2017-12-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2017-12-06 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | アップグレード | BofA/Merrill | Underperform → Neutral |
すべてを表示
Novo Nordisk Adr (NVO) 最新ニュース
2 Companies Poised to Capitalize on the Rise of GLP-1 Weight Loss Drugs - Morningstar
Is Novo Nordisk Stock a Buy? - The Motley Fool
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
Is Now The Time To Buy PDD Holdings Inc ADR (NASDAQ: PDD) Stock? - Stocks Register
Where Do Analysts Think The Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Is Going - Stocks Register
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
Precidian Investments Builds Out Its ADRhedged ETF Lineup with Four New Strategies, Offering Targeted International Exposure with Integrated Currency Hedge - Business Wire
Eli Lilly, Novo Nordisk Went Head-to-Head on Weight-Loss Drugs in 2024. There’s a Clear Winner. - Barron's
Is Alibaba Group Holding Ltd ADR’s (NYSE:BABA) Stock On The Decline? - Stocks Register
European Equities Traded in the US as American Depositary Receipts Start Week Down Slightly in Monday Trading - MSN
Will Novo Nordisk (NVO) Stock Recover To $145 Levels? - Forbes
Weekly Upgrades and Downgrades - InvestorPlace
Novo Nordisk Stock Crashes More Than 20% After Disappointing Obesity Drug Data. Eli Lilly Shares Soar. - Barron's
Markets News, December 20, 2024: Stocks Rise After Encouraging Inflation Data to Wrap Up Rough Week; Major Indexes Post Weekly Losses - Investopedia
Novo Nordisk: Shares Look Fairly Valued After CagriSema Disappointment - Morningstar
European Equities Traded in the US as American Depositary Fall in Wednesday Trading - MSN
Novo Nordisk A/S - GlobeNewswire Inc.
Novo Nordisk Just Got One Step Closer to Resolving Wegovy Supply Issue - Barron's
Lilly Tops Nordisk In Weightloss Battle - Real Investment Advice
Why Novo Nordisk A/S (NVO) Is the Best ADR Stock to Invest in? - Insider Monkey
12 Best ADR Stocks To Invest In According to Analysts - Insider Monkey
NVO Stock Quote Price and Forecast - CNN
European Equities Traded in the US as American Depositary Decline in Tuesday Trading - MSN
Novo Nordisk ADR (NYSE: NVO) Could Fell Another -55.9% - Stocks Register
Inside the Market Dominance of the Top 10 Pharma Giants - Value the Markets
Novo Nordisk Adr (NVO) 財務データ
収益
当期純利益
現金流量
EPS
0.50%
大文字化:
|
ボリューム (24 時間):